Edwards Lifesciences Corporation $EW Shares Acquired by Holocene Advisors LP

Holocene Advisors LP grew its stake in Edwards Lifesciences Corporation (NYSE:EW) by 0.9% during the third quarter, Holdings Channel.com reports. The fund owned 4,746,694 shares of the medical research company’s stock after acquiring an additional 42,717 shares during the period. Edwards Lifesciences accounts for about 0.8% of Holocene Advisors LP’s investment portfolio, making the stock its 16th biggest position. Holocene Advisors LP’s holdings in Edwards Lifesciences were worth $369,150,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in Edwards Lifesciences by 7.0% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after purchasing an additional 9,069 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Edwards Lifesciences by 13.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after buying an additional 10,078 shares during the period. Atlantic Union Bankshares Corp grew its stake in shares of Edwards Lifesciences by 2,240.9% in the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock valued at $925,000 after buying an additional 11,384 shares in the last quarter. OMERS ADMINISTRATION Corp grew its stake in shares of Edwards Lifesciences by 97.3% in the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after buying an additional 21,950 shares in the last quarter. Finally, Washington Trust Advisors Inc. raised its holdings in shares of Edwards Lifesciences by 15.6% in the 3rd quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after buying an additional 17,625 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Evercore reissued an “outperform” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research note on Monday, January 5th. Truist Financial set a $89.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, February 11th. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Tuesday, January 20th. Finally, Royal Bank Of Canada raised their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total transaction of $974,446.20. Following the completion of the transaction, the vice president owned 21,266 shares in the company, valued at approximately $1,827,387.38. The trade was a 34.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total value of $87,002.22. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,897,284.92. This trade represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 61,718 shares of company stock valued at $5,236,281. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Down 3.3%

EW stock opened at $81.82 on Monday. The company’s 50 day moving average price is $82.41 and its 200 day moving average price is $81.58. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The firm has a market capitalization of $47.52 billion, a price-to-earnings ratio of 44.71, a PEG ratio of 2.13 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter in the prior year, the firm earned $0.59 EPS. The firm’s revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.